Chemical neurolysis of the genicular nerves for chronic refractory knee pain: an observational cohort study
Pain Medicine · 2023
DOI: 10.1093/pm/pnad022 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Pain Medicine, 2023. Verfasst von Wassi Shaikh und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology, Northwestern Feinberg School of Medicine, Chicago, IL 60611, United States. Hauptthemen laut MEDLINE: Osteoarthritis, Knee, Nerve Block, Chronic Pain. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 30 Literaturangaben.
Abstract (Originalsprache)
Objective
Evaluate outcomes of genicular nerve chemical neurolysis (GChN) in a real-world population with chronic knee pain.
Design
Restrospective, observational cohort study.
Setting
Tertiary academic medical center. Subjects Consecutive patients who had undergone GChN ≥3 months prior.
Methods
Standardized surveys were collected by telephone and included the numerical rating scale, opioid analgesic use, and Patient Global Impression of Change. Age, sex, body mass index, duration of pain, history of arthroplasty, lack of effect from previous radiofrequency ablation, percentage relief from a prognostic block, and volume of phenol used at each injection site were extracted from charts. Descriptive statistics were calculated, and logistic regression analyses were performed to identify factors influencing treatment outcome.
Results
At the time of follow-up after GChN (mean ± SD: 9.9 ± 6.1 months), 43.5% (95% CI = 33.5–54.1) of participants reported ≥50% sustained pain reduction. On the Patient Global Impression of Change assessment, 45.9% (95% CI = 35.5–56.7) of participants reported themselves to be “very much improved” or “much improved.” Of 40 participants taking opioids at baseline, 11 (27.5%; 95% CI = 14.6–43.9) ceased use. Of participants with a native knee treated, 46.3% reported ≥50% pain reduction, whereas of participants with an arthroplasty in the treated knee, 33.3% reported this threshold of pain reduction (P = .326). Logistic regression analyses did not reveal associations between treatment success and any of the factors that we evaluated.
Conclusions
GChN could provide a robust and durable treatment effect in a subset of individuals with chronic knee pain with complicating factors traditionally associated with poor treatment outcomes, such as those with pain refractory to radiofrequency ablation or those who have undergone arthroplasty.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Anesthesiology, Northwestern Feinberg School of Medicine, Chicago, IL 60611, United States.
- Department of Physical Medicine and Rehabilitation, University of Utah School of Medicine, Salt Lake City, UT 84108, United States.
ORCID-Profile: Zachary L McCormick
Zitieren
APA
Shaikh, W., Miller, S., McCormick, Z. L., Patel, P. M., Teramoto, M., & Walega, D. R. (2023). Chemical neurolysis of the genicular nerves for chronic refractory knee pain: an observational cohort study. Pain Medicine. https://doi.org/10.1093/pm/pnad022
Vancouver
Shaikh W, Miller S, McCormick ZL, Patel PM, Teramoto M, Walega DR. Chemical neurolysis of the genicular nerves for chronic refractory knee pain: an observational cohort study. Pain Medicine. 2023. doi:10.1093/pm/pnad022
BibTeX
@article{Shaikh2023,
author = {Shaikh, Wassi and Miller, Scott and McCormick, Zachary L and Patel, Prachi Milan and Teramoto, Masaru and Walega, David R},
title = {Chemical neurolysis of the genicular nerves for chronic refractory knee pain: an observational cohort study},
journal = {Pain Medicine},
year = {2023},
doi = {10.1093/pm/pnad022}
}
EUVIMED